Chemical Works of Gedeon Richter Plc (RGEDF)
43.76
+0.45
(+1.04%)
USD |
OTCM |
Aug 25, 16:00
Chemical Works of Gedeon Richter Enterprise Value : 7.165B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 7.165B |
| August 24, 2026 | 7.083B |
| August 21, 2026 | 6.808B |
| August 20, 2026 | 6.808B |
| August 19, 2026 | 6.934B |
| August 18, 2026 | 6.791B |
| August 17, 2026 | 6.848B |
| August 14, 2026 | 6.951B |
| August 13, 2026 | 6.751B |
| August 12, 2026 | 6.855B |
| August 11, 2026 | 6.748B |
| August 10, 2026 | 6.500B |
| August 07, 2026 | 6.432B |
| August 06, 2026 | 6.113B |
| August 05, 2026 | 6.619B |
| August 04, 2026 | 6.173B |
| August 03, 2026 | 6.108B |
| July 31, 2026 | 6.094B |
| July 30, 2026 | 6.082B |
| July 29, 2026 | 5.945B |
| July 28, 2026 | 6.037B |
| July 27, 2026 | 5.936B |
| July 24, 2026 | 5.924B |
| July 23, 2026 | 5.925B |
| July 22, 2026 | 5.837B |
| Date | Value |
|---|---|
| July 21, 2026 | 6.165B |
| July 20, 2026 | 6.165B |
| July 17, 2026 | 6.214B |
| July 16, 2026 | 6.217B |
| July 15, 2026 | 6.103B |
| July 14, 2026 | 6.284B |
| July 13, 2026 | 6.109B |
| July 10, 2026 | 6.326B |
| July 09, 2026 | 6.105B |
| July 08, 2026 | 6.313B |
| July 07, 2026 | 6.313B |
| July 06, 2026 | 6.403B |
| July 02, 2026 | 6.433B |
| July 01, 2026 | 6.411B |
| June 30, 2026 | 6.403B |
| June 29, 2026 | 6.145B |
| June 26, 2026 | 6.316B |
| June 25, 2026 | 6.447B |
| June 24, 2026 | 6.187B |
| June 23, 2026 | 5.971B |
| June 22, 2026 | 6.059B |
| June 18, 2026 | 6.086B |
| June 17, 2026 | 6.269B |
| June 16, 2026 | 6.269B |
| June 15, 2026 | 6.347B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 552.52B |
| ANI Pharmaceuticals, Inc. | 1.972B |
| Corcept Therapeutics, Inc. | 13.04B |
| Veru, Inc. | 23.10M |
| Avadel Pharmaceuticals Plc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 122.85M |
| Revenue (Quarterly) | 777.18M |
| Total Expenses (Quarterly) | 653.98M |
| EPS Diluted (Quarterly) | 0.6729 |
| Gross Profit Margin (Quarterly) | 70.03% |
| Profit Margin (Quarterly) | 15.81% |
| Earnings Yield | 8.23% |
| Operating Earnings Yield | 12.53% |
| Normalized Earnings Yield | 8.226 |